ed in 60% of patients by Week 96.1

In this study, mezagitamab was generally well tolerated with no new safety concerns identified. No serious adverse events (AEs), including no serious hypersensitivity or injection-related reactions, discontinuations due to AEs, opportunistic infections or grade ≥3 infections were reported.1

“These promising data reinforce our belief in the potential of mezagitamab to redefine how autoimmune diseases like IgA nephropathy are treated – by targeting their root cause,” said Obi Umeh, M.D., M.Sc., Vice President, Franchise Global Program Leader at Takeda. “With patient enrollment ongoing in our Phase 3 trials investigating mezagitamab in IgA nephropathy and immune thrombocytopenia, we are excited to advance these promising programs and remain committed to bringing innovative solutions to patients with high unmet need.”

Mezagitamab is currently in Phase 3 clinical development for the treatment o
=*=*=*=*=*=
当前为第4/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页